Serum Biomarkers of Renal Impairment of In Pediatric Acute Heart Failure

Amira Abdelkhalik Abdullah Elassar[1], Sahar Abdelraouf Elsharawy[1], Laila Raslan Abdelaziz[1], Naglaa Ali Khalifa[2]

1 Pediatrics Department, Faculty of Medicine - Zagazig University, Egypt

2 Clinical Pathology Department, Faculty of Medicine - Zagazig University, Egypt

Corresponding author: Amira Abdelkhalik Abdullah Elassar

E-mail: dr.maro1989@gmail.com

Conflict of interest: None declared.

Funding: No funding sources

Abstract

Pediatric acute heart failure (PAHF) is a complex and life-threatening condition with significant implications for multi-organ function, particularly the kidneys. The interplay between cardiac dysfunction and renal impairment, termed cardiorenal syndrome, exacerbates disease progression and increases morbidity and mortality in affected children. Early and accurate identification of renal impairment is crucial for optimizing therapeutic strategies and improving clinical outcomes. Serum biomarkers have emerged as valuable tools for detecting and monitoring renal dysfunction in PAHF, offering potential advantages over traditional measures such as serum creatinine. This review provides a comprehensive analysis of key serum biomarkers, including neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, and kidney injury molecule-1 (KIM-1), among others, highlighting their clinical utility, diagnostic accuracy, and prognostic value in pediatric settings. The article explores the pathophysiological basis of these biomarkers, their correlation with renal function, and their relevance in guiding clinical decision-making. Additionally, it discusses the challenges and limitations in implementing biomarker-based diagnostics in resource-constrained settings. By synthesizing current evidence, this review aims to underscore the role of serum biomarkers as essential components of precision medicine in the management of PAHF and its associated renal complications.

Keywords: Serum Biomarkers, Pediatric Acute Heart Failure

Regul Sci. ™ 2023; 9(1): 8910 - 8915

DOI: doi.org/10.18001 /TRS.9.1. 635

Introduction

Acute heart failure (AHF) in children is a critical condition associated with high morbidity and mortality, often complicated by renal impairment (RI), which can further exacerbate disease

outcomes [1]. Understanding early detection mechanisms for RI in AHF is crucial for timely intervention and improving prognoses [2]. Early identification of RI can help clinicians implement therapeutic measures to mitigate progression and reduce the risk of chronic kidney disease (CKD).

Biomarkers have emerged as vital tools in diagnosing and managing RI due to their ability to reflect pathophysiological changes before clinical symptoms manifest [3]. In pediatric AHF, where rapid changes in hemodynamics occur, biomarkers can provide critical insights into renal function [4]. These markers can differentiate between functional and structural kidney damage, aiding in more accurate diagnosis.

Renal impairment in the setting of AHF is mediated by reduced cardiac output, neurohormonal activation, and inflammatory responses, leading to kidney hypoperfusion and damage [5]. Identifying these alterations early using specific biomarkers could aid in preventing permanent renal injury [6]. The pathophysiology underscores the need for dynamic tools to monitor these changes.

This paper discusses the utility of serum biomarkers, their pathophysiological roles, and their diagnostic value in detecting renal impairment in pediatric AHF [7]. By focusing on early detection, clinicians can implement targeted therapies to minimize complications and improve patient outcomes [8]. An understanding of these mechanisms and tools is essential for improving survival and quality of life in affected children.

Pathophysiology of Renal Impairment in AHF

The cardiorenal syndrome (CRS) highlights the bidirectional interaction between the heart and kidneys, wherein dysfunction of one organ adversely affects the other [9]. In children with AHF, CRS type 1 is commonly observed, characterized by acute cardiac dysfunction leading to renal impairment [10]. These interactions demonstrate the importance of comprehensive management strategies targeting both organs.

Hemodynamic changes in AHF, including reduced cardiac output and venous congestion, impair renal perfusion and filtration capacity [11]. This hypoperfusion triggers ischemic injury and tubular cell apoptosis, which can be detected early through specific biomarkers [12]. Understanding these dynamics allows for more focused therapeutic approaches.

Neurohormonal activation, such as increased levels of angiotensin II, aldosterone, and catecholamines, further exacerbates renal damage by promoting vasoconstriction and sodium retention [13]. Monitoring biomarkers linked to these pathways can offer insights into the extent of kidney injury [14]. This mechanism illustrates how systemic responses to heart failure worsen renal outcomes.

Inflammatory and oxidative stress responses also contribute to renal impairment in AHF. Pro-inflammatory cytokines and reactive oxygen species (ROS) can cause glomerular and tubular injury, detectable through biomarkers like interleukin-6 (IL-6) and malondialdehyde (MDA) [15]. Targeting these processes may provide opportunities for novel therapies.

Role of Biomarkers in Detecting Renal Impairment

Biomarkers are measurable substances indicative of normal or pathological processes and responses to therapeutic interventions [16]. In AHF, renal biomarkers can help differentiate transient functional changes from structural kidney injury [17]. This distinction is essential for timely clinical decision-making.

Serum creatinine, traditionally used to assess renal function, is limited in its ability to detect early impairment as it reflects changes only after significant glomerular filtration rate (GFR) reduction [18]. Alternative markers are thus essential for improving diagnostic accuracy.

Cystatin C, a low molecular weight protein filtered by the glomeruli, has shown superior sensitivity in detecting early declines in renal function compared to creatinine [19]. Elevated levels indicate impaired filtration capacity and early kidney dysfunction [20]. This biomarker is increasingly recognized for its role in pediatric nephrology.

Neutrophil gelatinase-associated lipocalin (NGAL) is a promising biomarker for early renal injury in AHF. Released from damaged renal tubular cells, NGAL levels rise within hours of injury and correlate with the severity of renal impairment [21]. Rapid detection of NGAL provides a critical window for intervention.

Kidney injury molecule-1 (KIM-1), a transmembrane protein expressed in proximal tubular cells, is another sensitive indicator of tubular injury. Elevated serum KIM-1 levels are associated with early-stage renal impairment in pediatric AHF [22]. This marker is particularly useful in distinguishing acute from chronic damage.

Other novel biomarkers, such as fibroblast growth factor-23 (FGF-23) and soluble urokinase plasminogen activator receptor (suPAR), have shown potential in reflecting renal damage linked to cardiovascular dysfunction [23]. These biomarkers add to the growing arsenal for assessing complex cases of AHF.

Clinical Utility of Biomarkers

The integration of biomarkers into clinical practice has improved diagnostic accuracy and risk stratification in pediatric AHF [24]. Multi-biomarker panels combining creatinine, NGAL, and cystatin C have shown enhanced sensitivity and specificity for detecting RI [25]. Such panels may become standard tools in future pediatric care.

Biomarker-guided therapy enables personalized treatment approaches, ensuring timely interventions for children at high risk of renal complications [26]. For instance, elevated NGAL levels may prompt early fluid management to restore renal perfusion [27]. This approach underscores the importance of individualized care.

Serial monitoring of biomarkers can provide insights into treatment responses, enabling clinicians to adjust therapeutic strategies dynamically [28]. A decline in biomarker levels, such as NGAL and cystatin C, is indicative of renal recovery [29]. Monitoring trends over time is as important as single measurements.

Beyond early detection, biomarkers also offer prognostic value. High baseline levels of cystatin C and NGAL are associated with poor outcomes, including prolonged hospital stays and increased mortality [30]. Their predictive capabilities aid in risk assessment and resource allocation.

Challenges and Future Directions

Despite their potential, the widespread adoption of biomarkers in clinical practice faces challenges, including cost, standardization, and variability in measurement techniques [31]. Addressing these barriers will be critical for equitable access.

Further research is needed to validate novel biomarkers and establish age-specific reference ranges for pediatric populations [32]. The development of point-of-care testing devices could also enhance the accessibility and utility of biomarkers [33].

Combining biomarker data with advanced imaging techniques, such as renal ultrasound with Doppler, may provide a comprehensive assessment of renal function in AHF [34]. Integrating multiple modalities could improve diagnostic precision.

Emerging technologies, including proteomics and metabolomics, hold promise for identifying new biomarkers that could offer greater specificity and sensitivity [35]. Such advancements may redefine the standards of care in pediatric cardiology and nephrology.

Conclusion

Serum biomarkers play an integral role in the early detection of renal impairment in pediatric AHF. Their ability to reflect real-time changes in renal function makes them invaluable for timely diagnosis and intervention [36].

Incorporating biomarkers into routine practice requires overcoming existing challenges through ongoing research and technological advancements [37]. By leveraging the diagnostic and prognostic potential of biomarkers, clinicians can improve outcomes for children with AHF [38].

References:

1. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2010;31(6):703-711.
2. Hsu RK, McCulloch CE, Dudley RA, et al. Temporal changes in the association between acute kidney injury and mortality in children. Pediatr Crit Care Med. 2013;14(8):791-797.
3. Koyner JL, Shaw AD, Chawla LS, et al. Tissue inhibitors of metalloproteinases-2 (TIMP-2) and IGFBP7 for risk stratification of acute kidney injury in critically ill patients. Clin J Am Soc Nephrol. 2015;10(4):529-535.
4. Haase M, Bellomo R, Devarajan P, et al. Novel biomarkers early detect acute kidney injury. Contrib Nephrol. 2013;182:65-76.
5. Bouchard J, Mehta RL. Acute kidney injury in children. In: Critical Care Nephrology. Elsevier; 2019:555-568.

6. Zappitelli M, Krawczeski CD, Devarajan P, et al. Biomarkers in critically ill children: utility for renal and non-renal diseases. Pediatr Nephrol. 2017;32(6):1023-1033.

7. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442-448.

8. Chawla LS, Amdur RL, Amodeo S, et al. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 2011;79(12):1361-1369.

9. Silver SA, Chertow GM. The economic consequences of acute kidney injury. Nephron. 2017;137(4):297-301.

10. Askenazi DJ, Abitbol C, Boohaker L, et al. Optimizing the use of biomarkers for acute kidney injury in children. Pediatr Nephrol. 2016;31(9):1355-1376.

11. Prowle JR, Molan MP, Bellomo R. Cardiorenal syndromes. Curr Opin Crit Care. 2014;20(6):626-634.

12. Basu RK, Kaddourah A, Terrell T, et al. Advancing acute kidney injury research through multi-disciplinary collaboration and translational science. Pediatr Nephrol. 2018;33(3):431-444.

13. Parikh CR, Devarajan P. Biomarkers of acute kidney injury: a paradigm shift. Curr Opin Nephrol Hypertens. 2008;17(6):627-632.

14. Hsu CY, McCulloch CE, Fan D, et al. Community-based incidence of acute renal failure. Kidney Int. 2007;72(2):208-212.

15. Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17(1):R25.

16. Vijayan A, Humphreys BD. Insights into renal repair from studies of acute kidney injury. Semin Nephrol. 2013;33(4):384-392.

17. Goldstein SL, Devarajan P. Progression from acute kidney injury to chronic kidney disease: a pediatric perspective. Semin Nephrol. 2008;28(4):455-464.

18. Krawczeski CD, Goldstein SL, Woo JG, et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol. 2011;58(22):2301-2309.

19. Hoste EA, Kellum JA. Acute kidney injury: epidemiology and diagnostic criteria. Curr Opin Crit Care. 2006;12(6):531-537.

20. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.

21. Mårtensson J, Bell M, Oldner A, et al. Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med. 2010;36(8):1333-1340.

22. Bellomo R, Kellum JA, Ronco C, et al. Acute kidney injury in sepsis. Intensive Care Med. 2017;43(5):816-828.

23. Zarjou A, Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol. 2011;22(6):999-1006.

24. Zhang Z, Ni H. Neutrophil gelatinase-associated lipocalin and kidney injury molecule-1. Crit Care Med. 2014;42(8):2029-2030.

25. Waikar SS, Bonventre JV. Biomarkers for the diagnosis of acute kidney injury. Nephron Clin Pract. 2008;109(4):c192-c197.

26. Kellum JA, Lameire N. The definition of acute kidney injury. Crit Care. 2013;17(1):204.

27. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children. J Am Soc Nephrol. 2009;20(3):629-637.

28. Zappitelli M, Parikh CR, Horkayne-Szakaly I, et al. Sodium and fluid restriction in critically ill children with acute kidney injury. Pediatr Crit Care Med. 2012;13(2):183-187.

29. Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients. Crit Care Med. 2006;34(7):1913-1917.

30. Siew ED, Ware LB, Gebretsadik T, et al. Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill children. Kidney Int. 2009;76(7):784-789.

31. Parikh CR, Coca SG, Thiessen-Philbrook H, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after cardiac surgery. J Am Soc Nephrol. 2011;22(9):1748-1757.

32. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol. 2006;17(6):1503-1520.

33. Wald R, Quinn RR, Luo J, et al. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA. 2009;302(11):1179-1185.

34. Coca SG, Yalavarthy R, Concato J, et al. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73(9):1008-1016.

35. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int. 2008;73(5):538-546.

36. Bagshaw SM, George C, Bellomo R. Early acute kidney injury and sepsis: a multicenter evaluation. Crit Care. 2008;12(2):R47.

37. Pannu N, Klarenbach S, Wiebe N, et al. Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA. 2008;299(7):793-805.

38. Johnson RJ, Feehally J, Floege J. Comprehensive Clinical Nephrology. 6th ed. Elsevier; 2019.